Search Results 761-770 of 19265 for Hemoglobin

1. Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers - Mayo Clinic

   - Hemoglobin >= 9.0 g/dL (patients may be transfused to meet hemoglobin [Hgb] requirement) (obtained =< 14 days prior to registration) - Absolute neutrophil ...

2. A Study Monitoring Potassium Levels in Patients with Cardiac and Renal Disease - Mayo Clinic

   Hemoglobin of < 8mg/dl in the last 30 days; Known or medically documented allergy to acrylic, hydrogel or silicone adhesives. Participating Mayo Clinic ...

3. Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer - Mayo Clinic

   ... hemoglobin ≥8 grams/deciliter. Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the treating physician.

4. A Study of Disease Risk Caused by Tumor Particles Getting into the Blood from Endoscopic Ultrasound Guided Fine Needle Aspiration - Mayo Clinic

   Anemia (Hemoglobin < 12.4 gm/dl for males and < 11.6 gm/dl for females); Pregnancy; < 18 years of age. More information. Publications. Publications are ...

5. A Study to Evaluate the Safety and Effectiveness of CAEL-101 and Plasma Cell Dyscrasia Treatment vs. Placebo and Plasma Cell Dyscrasia Tretment to Treat Patients with Mayo Stage IIIb AL Amyloidosis

   Anemia: hemoglobin value of \> 20 g/L below the lowest limit of normal, or a hemoglobin value \< 100 g/L OR iv. Bone lesions: one or more osteolytic lesion ...

6. A Study of SC-006 in Subjects With Advanced Cancer - Mayo Clinic

   Hemoglobin ≥.0 g/dL;; Serum total bilirubin ≤.5× ULN or ≤× ULN for subjects with Gilbert's disease;; Serum ALT and AST ≤× ULN (≤× ULN if evidence of ...

7. TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study) - Mayo Clinic

   Anemia with hemoglobin less than 8. Patients not willing to undergo a blood draw. Patients with stage IV or distant metastatic breast cancer. Eligibility ...

8. A Phase 1/2 Study To Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of HMB-001 In Glanzmann Thrombasthenia - Mayo Clinic

   Hemoglobin > 85 g/L and platelet count > 150 x 10^9/L at Screening. Part B Inclusion Criteria: 1. Has the ability to provide informed consent, and has an ...

9. A Study To Evaluate The Safety, Tolerability, And Effects On Blood And Urine Markers Of Single Ascending Dose Of GSK4771261 In Healthy Participants And Participants With Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

   Glycosylated hemoglobin (HbA1c) >=48 millimoles per mole (mmol/mol) (>=6.5%) at screening. Bone fracture within 6 months prior to screening, or presence of a ...

10. Comparison of Bone Quality in Subjects with or without Type 2 Diabetes - Mayo Clinic

    ... hemoglobin A1c < 5.7% (28)]. Subjects with fractures only of the skull and face, hands and fingers, feet and toes, patella, and ankle, sites which are not ...